PL441358A1 - Inhibitor aktywności transportera ABCC1 do zastosowania w leczeniu inwazyjnych stadiów nowotworu poprzez hamowanie ich zdolności inwazyjnych oraz kompozycja farmaceutyczna zawierająca taki inhibitor - Google Patents

Inhibitor aktywności transportera ABCC1 do zastosowania w leczeniu inwazyjnych stadiów nowotworu poprzez hamowanie ich zdolności inwazyjnych oraz kompozycja farmaceutyczna zawierająca taki inhibitor

Info

Publication number
PL441358A1
PL441358A1 PL441358A PL44135822A PL441358A1 PL 441358 A1 PL441358 A1 PL 441358A1 PL 441358 A PL441358 A PL 441358A PL 44135822 A PL44135822 A PL 44135822A PL 441358 A1 PL441358 A1 PL 441358A1
Authority
PL
Poland
Prior art keywords
inhibitor
invasive
inhibiting
pharmaceutical composition
composition containing
Prior art date
Application number
PL441358A
Other languages
English (en)
Other versions
PL245697B1 (pl
Inventor
Wojciech Ciszewski
Katarzyna Sobierajska
Andrzej BŁAUŻ
Original Assignee
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL441358A priority Critical patent/PL245697B1/pl
Publication of PL441358A1 publication Critical patent/PL441358A1/pl
Publication of PL245697B1 publication Critical patent/PL245697B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest niskocząsteczkowy inhibitor białka ABCC1 do zastosowania w hamowaniu zdolności inwazyjnej komórek nowotworowych oraz kompozycja farmaceutyczna zawierająca niskocząsteczkowy inhibitor białka ABCC1.
PL441358A 2022-06-02 2022-06-02 Niskocząsteczkowy inhibitor białka ABCC 1 do zastosowania w hamowaniu metastatycznych komórek raka jelita grubego PL245697B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL441358A PL245697B1 (pl) 2022-06-02 2022-06-02 Niskocząsteczkowy inhibitor białka ABCC 1 do zastosowania w hamowaniu metastatycznych komórek raka jelita grubego

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441358A PL245697B1 (pl) 2022-06-02 2022-06-02 Niskocząsteczkowy inhibitor białka ABCC 1 do zastosowania w hamowaniu metastatycznych komórek raka jelita grubego

Publications (2)

Publication Number Publication Date
PL441358A1 true PL441358A1 (pl) 2023-12-04
PL245697B1 PL245697B1 (pl) 2024-09-23

Family

ID=89033605

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441358A PL245697B1 (pl) 2022-06-02 2022-06-02 Niskocząsteczkowy inhibitor białka ABCC 1 do zastosowania w hamowaniu metastatycznych komórek raka jelita grubego

Country Status (1)

Country Link
PL (1) PL245697B1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069950A2 (en) * 2001-03-01 2002-09-12 Eli Lilly And Company Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
WO2016029127A1 (en) * 2014-08-22 2016-02-25 The Regents Of The University Of Colorado, A Body Corporate Dot1l inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069950A2 (en) * 2001-03-01 2002-09-12 Eli Lilly And Company Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5
WO2016029127A1 (en) * 2014-08-22 2016-02-25 The Regents Of The University Of Colorado, A Body Corporate Dot1l inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F. G. LOW ET AL.:: "Int. J. Mol. Sci.; 2020, 21, 7664", "ROLES OF ABCC1 AND ABCC4 IN PROLIFERATION AND MIGRATION OF BREAST CANCER CELL LINES" *

Also Published As

Publication number Publication date
PL245697B1 (pl) 2024-09-23

Similar Documents

Publication Publication Date Title
WO2022221528A3 (en) Kras g12c inhibitors
WO2024238633A3 (en) Kras g12s and g12c inhibitors
MX2025011950A (es) Inhibidores macrociclicos de ras
Retsky et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
TR200102020T2 (tr) Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
Abraham et al. Optimal management of digital ulcers in systemic sclerosis
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
MX2025012181A (es) Formas cristalinas de inhibidores de ras, composiciones que las contienen y metodos para su uso
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
Turtiainen et al. Surgical wound infections after peripheral vascular surgery
EA202192746A1 (ru) Гетероциклические соединения и их применение
MX2024000986A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.
DK4039688T3 (da) Substitueret pyrrolopyrimidin og pyrazolopyrimidin som brutons tyrosinkinase- (btk) nedbrydere
CO2023012342A2 (es) Inhibidores de enzimas
WO2020205646A3 (en) Small molecule parg inhibitors and methods of use thereof
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).
CL2025003070A1 (es) Formas cristalinas de un inhibidor de ras.
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
WO2024227174A3 (en) Antibodies that bind ox40l and methods of use